Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S3: prohibited at all times; Specified. No dose-based inhaled exception is stated for this substance. [1]
S3; printed p. 9 and relevant S5 note, p. 12 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulations
Levosalbutamol is called levalbuterol in the US Xopenex HFA label. The metered inhalation aerosol treats or prevents bronchospasm in specified patients with reversible obstructive airway disease. [2]
- Product and jurisdiction specific; this is not an exhaustive brand, indication or route inventory.
Selected health warnings
The label warns about paradoxical bronchospasm, cardiovascular effects, excessive use, low potassium and altered blood glucose. WADA explicitly distinguishes this single-enantiomer drug from racemic salbutamol; the salbutamol exception does not transfer to it. [2] [3]
- No treatment dose, device conversion or personal eligibility determination is provided.
Do not transfer another drug’s exception
WADA explicitly states that levosalbutamol is different from racemic salbutamol and does not receive its dose-based inhaled exception. [3]
- A prescription is not itself a TUE or sport eligibility clearance.
What remains uncertain
- No exact ordinary-food or supplement-contamination pathway was established by the retained sources; this is a research limitation, not proof of absence.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Xopenex HFA levalbuterol US label ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
- WADA Prohibited List FAQ ↗Accessed 2026-11-10 · Relevant document text opened
S3/S5 text and relevant FAQ answers
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.